How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Policy 0070 is a ground-breaking initiative and the European Medicines Agency (EMA) represents the first agency on a global level that will grant access to clinical trial data on such a large scale. With the requirements for all non-Covid products expected to restart in 2023, there is preparation required for qualifying submissions – which include new marketing authorization applications (MAAs) and clinical variations.


Open PDF

Return to Insights Center

Related Insights

Blog

New FDA draft guidance: Implications for simplifying interchangeability for biosimilars in the US

Jul 16, 2024

Article

Relyvrio Approval: Lessons Learned

Oct 31, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022

Article

EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Playbook

Are you using real-world evidence?

Feb 1, 2023